Massive study tracks Real-World breast cancer care in china

This study looks at how patients with HR+/HER2- advanced or metastatic breast cancer are actually treated in China, and how well those treatments work. Researchers will analyze data from 14,000 patients to see which first-line therapies are used, how often patients switch treatments, and how long they stay on each therapy. The goal is to fill gaps in knowledge about real-world outcomes, especially for newer drugs like ribociclib.